Literature DB >> 25217500

Transcatheter aortic valve implantation combined with elective coronary artery stenting: a simultaneous approach†.

Adam Penkalla1, Miralem Pasic2, Thorsten Drews1, Semih Buz1, Stephan Dreysse1, Marian Kukucka1, Alexander Mladenow1, Roland Hetzer1, Axel Unbehaun1.   

Abstract

OBJECTIVES: Many patients referred for transcatheter aortic valve implantation (TAVI) also require percutaneous coronary intervention (PCI). The aim of the study was to identify whether combined treatment of patients with aortic stenosis and coronary artery disease (CAD) with TAVI and PCI has comparable results to treatment of patients with no CAD or with CAD with non-significant lesions who receive only TAVI.
METHODS: Between April 2008 and August 2013, 730 consecutive patients underwent transapical TAVI at our institution. In our study population of 593 patients, 285 (48.1%) had no CAD and received TAVI only (Group I); 232 (39.1%) presented with CAD but no highly significant coronary artery lesion(s) and also received TAVI only (Group II), and 76 (12.8%) had CAD and highly significant coronary lesion(s) and underwent combined, single-staged TAVI and PCI (Group III). Three transapical TAVI patients who received PCI because of iatrogenic coronary artery obstruction during TAVI and 134 transapical TAVI patients with previous CABG were excluded from this study.
RESULTS: Group II showed a calculated mean SYNTAX score of 5.7 ± 7.4. However, Group III showed a statistically significantly higher mean SYNTAX score of 8.0 ± 5.7 than Group II (P < 0.001) before the combined procedure. Combined TAVI and PCI reduced the mean SYNTAX score significantly from 8.0 ± 5.7 to 3.0 ± 4.9 (P < 0.001) in those patients presenting with severe aortic stenosis and highly significant CAD (Group III). The thirty-day all-cause mortality rate was 5.3, 3.9 and 2.6% for Group I, II and III, respectively (P = 0.609). Patients with highly significant CAD undergoing TAVI and PCI had similar survival up to 3 years as patients without CAD undergoing TAVI only. Radiation time and amount of contrast agent were higher during combined treatment in Group III (P < 0.05). However, no difference in acute kidney injury post-procedurally was observed.
CONCLUSIONS: Single-stage combined treatment of severe aortic stenosis and highly relevant coronary lesions is a safe and feasible procedure. Early survival and survival up to 3 years are comparable to that observed in patients presenting without CAD who received TAVI only. PCI effectively reduces the complexity of coronary lesions. Although more contrast agent is applied during the combined treatment, the rate of acute kidney injury was not higher.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Aortic valve stenosis; Coronary artery disease; Percutaneous coronary intervention; Transcatheter aortic valve implantation

Mesh:

Year:  2014        PMID: 25217500     DOI: 10.1093/ejcts/ezu339

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  13 in total

Review 1.  Coronary Revascularisation in Transcatheter Aortic Valve Implantation Candidates: Why, Who, When?

Authors:  Davide Cao; Mauro Chiarito; Paolo Pagnotta; Bernhard Reimers; Giulio G Stefanini
Journal:  Interv Cardiol       Date:  2018-05

Review 2.  Mechanical circulatory support in patients with severe aortic stenosis and left ventricular dysfunction undergoing percutaneous coronary intervention.

Authors:  Mohamad Alkhouli; Ahmed Al Mustafa; Zakeih Chaker; Fahad Alqahtani; Sami Aljohani; David R Holmes
Journal:  J Card Surg       Date:  2017-03-07       Impact factor: 1.620

Review 3.  Timing and Outcomes of PCI in the TAVR Era.

Authors:  Konstantinos V Voudris; Peter Petropulos; Panagiotis Karyofillis; Konstantinos Charitakis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-06

Review 4.  Assessment, treatment, and prognostic implications of CAD in patients undergoing TAVI.

Authors:  Edward Danson; Peter Hansen; Sayan Sen; Justin Davies; Ian Meredith; Ravinay Bhindi
Journal:  Nat Rev Cardiol       Date:  2016-02-11       Impact factor: 32.419

Review 5.  Long term outcomes of transcatheter aortic valve implantation (TAVI): a systematic review of 5-year survival and beyond.

Authors:  Adam Chakos; Ashley Wilson-Smith; Sameer Arora; Tom C Nguyen; Abhijeet Dhoble; Giuseppe Tarantini; Matthias Thielmann; John P Vavalle; Daniel Wendt; Tristan D Yan; David H Tian
Journal:  Ann Cardiothorac Surg       Date:  2017-09

6.  Transcatheter aortic valve implantation facilitated by right common carotid cut-down and innominate artery angioplasty with simultaneous right coronary artery vein graft percutaneous coronary intervention in a patient with mid aortic syndrome: a case report.

Authors:  Mina S A Ghobrial; Kamal Khan; Mohamed Baguneid; Richard D Levy
Journal:  Eur Heart J Case Rep       Date:  2020-05-26

7.  ROTAVI: simultaneous left main rotablation and transcutaneous aortic valve implantation in calcified coronaries and severe aortic stenosis - a case report.

Authors:  Himanshu Gupta; Navjyot Kaur; Yashpaul Sharma; Parag Barwad
Journal:  Eur Heart J Case Rep       Date:  2020-08-23

Review 8.  The safety of concomitant transcatheter aortic valve replacement and percutaneous coronary intervention: A systematic review and meta-analysis.

Authors:  Yong Yang; Fang-Yang Huang; Bao-Tao Huang; Tian-Yuan Xiong; Xiao-Bo Pu; Shi-Jian Chen; Mao Chen; Yuan Feng
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 9.  Transcatheter Aortic Valve Implantation With or Without Percutaneous Coronary Artery Revascularization Strategy: A Systematic Review and Meta-Analysis.

Authors:  Rafail A Kotronias; Chun Shing Kwok; Sudhakar George; Davide Capodanno; Peter F Ludman; Jonathan N Townend; Sagar N Doshi; Saib S Khogali; Philippe Généreux; Howard C Herrmann; Mamas A Mamas; Rodrigo Bagur
Journal:  J Am Heart Assoc       Date:  2017-06-27       Impact factor: 5.501

Review 10.  Bioprosthetic Aortic Valve Replacement in <50 Years Old Patients - Where is the Evidence?

Authors:  Amer Harky; Michael Man Yuen Suen; Chris Ho Ming Wong; Abdul Rahman Maaliki; Mohamad Bashir
Journal:  Braz J Cardiovasc Surg       Date:  2019-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.